dolastatin 10

DRUG7 trials

Sponsors

University of Chicago, Barbara Ann Karmanos Cancer Institute, M.D. Anderson Cancer Center, National Cancer Institute (NCI), Mayo Clinic

Conditions

Extrahepatic Bile Duct CancerGallbladder CancerKidney CancerLeukemiaLiver CancerLymphomaMyelodysplastic SyndromesOvarian Cancer

Phase 1

Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

CompletedNCT00003693

M.D. Anderson Cancer CenterLeukemia, Myelodysplastic Syndromes

Start: 1998-12-18End: 2001-10-30Updated: 2018-10-25

Phase 2

Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

CompletedNCT00005579

University of VermontLeukemia, Lymphoma

Start: 1998-06-30End: 2003-02-28Updated: 2013-06-26

Dolastatin 10 in Treating Patients With Advanced Kidney Cancer

CompletedNCT00003914

Mayo ClinicKidney Cancer

Start: 1999-08-31End: 2009-05-31Target: 30Updated: 2011-05-11

Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer

CompletedNCT00003677

M.D. Anderson Cancer CenterPancreatic Cancer

Start: 1999-02-01End: 2002-01-16Updated: 2018-10-25

Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer

CompletedNCT00003557

University of ChicagoExtrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer

Start: 1999-01-31End: 2003-08-31Updated: 2014-03-06

Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy

CompletedNCT00003626

Barbara Ann Karmanos Cancer InstituteProstate Cancer

Start: 1998-10-31End: 2000-05-31Updated: 2013-04-05

Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma

CompletedNCT00003778

National Cancer Institute (NCI)Ovarian Cancer, Sarcoma

Start: 1999-04-30Updated: 2013-02-08